Bio X Cell launched a ready-to-use, anti-mouse trispecific antibody targeting PD-L1 × TIGIT × LAG3 in a murine IgG2a format for standard mouse models. The catalog product is designed to support combinatorial checkpoint biology testing in a single reagent rather than multi-agent dosing setups. The trispecific format is intended to reduce variability and complexity in preclinical experiments while enabling investigators to probe T-cell exhaustion and immune suppression across three pathways simultaneously. Bio X Cell said the product is manufactured to in vivo-ready standards, including low endotoxin levels. The announcement is positioned as a tool-market signal: preclinical immuno-oncology workflows are demanding reagents that reflect clinical combinatorial strategies more directly. For R&D teams, the shift is about faster experimental iteration and more reproducible designs when assessing whether multi-checkpoint engagement improves antitumor responses.